engleski

PCSK9 inhibitors in clinical practice: Expectations and reality

There is no doubt today that lowering LDL- cholestrol (LDL-C) reduces atherosclerotic cardiovascular disease (ASCVD) morbidity and mortality [1]. Statins are the established treatment of choice for lowering LDL-C since the early 90s and in secondary, but also primary prevention, they can reduce ASCVD morbidity and mortality [2]. Nevertheless, a number of patients, particularly those with familial hypercholesterolaemia (FH), are unable to achieve LDL-C target values, as recommended by the guidelines, even with high doses of more potent statins [3–5].

alirocumab ; evolocumab ; familial hypercholesterolaemia ; LDL-cholesterol ; PCSK9 inhibitors ; statin intolerance

nije evidentirano